Abstract
BackgroundThe beneficial effects of polyphenols have been reported. This study aimed to investigate the effect of oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin1 (SIRT1) in type 2 diabetics.MethodsIn this double-blind, randomized clinical trial, 44 diabetic patients were selected. Patients were assigned to the intervention group (22 subjects) and placebo (22 subjects) and received a capsule containing 180 mg of EA per day or placebo for eight weeks, respectively. At the beginning and end of the study, anthropometric indices, fasting plasma glucose (FPG), plasma insulin level, IR, Fetuin-A, and SIRT1 were measured. Statistical analysis was performed using SPSS software.ResultsAt the beginning and end of the study, there was no significant difference between the two groups regarding anthropometric indices (P > 0.05). At the end of the survey, EA supplementation significantly reduced FPG, insulin, IR, and Fetuin-A and increased SIRT1 levels compared with the placebo group (P < 0.05). However, these changes were not significant in the placebo group (P > 0.05).ConclusionEA with antioxidant properties plays an essential role in reducing the macrovascular and microvascular complications of diabetes by reducing inflammation and insulin resistance.Trial registration The protocol of this clinical trial is registered with the Iranian Registry of Clinical Trials (http://www.IRCT.IR, identifier: IRCT20141025019669N13)
Highlights
IntroductionThis study aimed to investigate the effect of oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin (SIRT1) in type 2 diabetics
The beneficial effects of polyphenols have been reported
Ellagic acid (EA) is a polyphenol found in various fruits, including berries, raspberries, pomegranates, and walnuts [14]. Due to this polyphenol’s antioxidant property and the possibility of its favorable effect on SIRT1 and Fetuin-A levels and reduced insulin resistance, this study aimed to investigate the effect of EA oral supplement on SIRT1, Fetuin-A, and insulin resistance in patients with type 2 diabetes
Summary
This study aimed to investigate the effect of oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin (SIRT1) in type 2 diabetics. There are factors and cytokines that play a stimulating or inhibitory role in insulin function. Silent information regulator 1 (SIRT1) proteins, known as sirtuins, were identified as genetic silencing factors. SIRT1 is a NAD-dependent histone deacetylase that senses oxidative stress conditions and increases a protective cellular response. To regulate transcription, it transfers acetyl groups from the amino acids N-acetyl lysine in DNA histones. It transfers acetyl groups from the amino acids N-acetyl lysine in DNA histones It is expressed in the brain, heart, liver, pancreas, skeletal muscle, spleen, and adipose tissue. SIRT1 plays a vital role in the pathology, progression, and treatment of several diseases, including neurological disorders such as Alzheimer’s disease, cardiovascular disease, metabolic disease, and aging-related disease [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
